Welcome to our dedicated page for Immunocore Holdings news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings stock.
Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
The FAK inhibitors market is set for significant growth from 2019 to 2032, driven by emerging therapies with enhanced safety profiles and novel delivery methods for various cancers. Key companies, including Verastem, GlaxoSmithKline, Merck, and Immunocore (IMCR), are actively developing FAK inhibitors. Notable therapies under development include VS-6766 + defactinib and KIMMTRAK (tebentafusp), with several others awaiting approval. However, market expansion may be restricted by factors like therapy failures, high pricing, and access challenges. The report emphasizes the increasing focus on molecular therapies as traditional cytotoxic treatments have not yet cured cancer, highlighting the importance of FAK inhibitors for future oncology treatments.
Engimmune Therapeutics has announced a leadership transition as Dr. Søren Mouritsen steps down as CEO, with Dr. Lars Nieba appointed as his successor. This transition is part of a planned strategy to advance the company's T-cell receptor (TCR)-based therapeutics development. Dr. Nieba brings over 25 years of experience in biopharmaceuticals, including leadership roles at Roche and Bayer, which positions him well to enhance Engimmune's strategic direction. Under Dr. Mouritsen's leadership, the company was established and successfully completed seed financing. Board Chairman Bent Jakobsen and other leaders expressed confidence in Nieba's ability to navigate the next stages of development, leveraging Engimmune's innovative technologies. Engimmune focuses on TCR therapies aimed at treating cancer and autoimmune diseases, utilizing advanced methodologies such as genome editing and machine learning.
Immunocore Holdings plc (Nasdaq: IMCR) presented new data on KIMMTRAK (tebentafusp-tebn) at the 2023 American Association for Cancer Research Annual Meeting. The Phase 3 trial indicated that early reductions in circulating tumor DNA (ctDNA) correlate with improved overall survival (OS). With 46 months of median follow-up from the Phase 2 trial, the median OS was confirmed at 16.8 months, significantly higher than historical rates in metastatic uveal melanoma (mUM). Additionally, ctDNA reduction by week 9 was noted in 88% of first-line patients, and those achieving ctDNA clearance saw an 84% one-year OS. Immunocore plans to release further OS data from the Phase 3 trial later in 2023.